Disposable Insulin Pumps Prior Authorization
Customize your policy alerts
Sign up for all mediviewcurative policy alerts
Know when mediviewcurative releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements for disposable insulin infusion pumps (eg, Omnipod products) for members of Curative Health Plan; applies to initial and continued therapy determinations for insulin-requiring diabetes.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy — Covered when ALL of the following are met for initial therapy.
Covered when ALL of the following are met for initial therapy:
Initial Therapy
Diagnosis
- Type 1 diabetes (chart notes within past 180 days)
- Type 2 diabetes mellitus requiring insulin therapy (chart notes within past 180 days)
- For Type 2 diabetes: patient is on an insulin regimen of 3 or more injections per day
- Patient performs 4 or more blood glucose tests per day OR is using Continuous Glucose Monitoring (CGM)
Clinical criteria (one required while compliant on optimized MDI)
- Glycated hemoglobin (HbA1c) greater than 7%
- History of recurring hypoglycemia
- Wide fluctuations in blood glucose
- Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dL
- History of severe glycemic excursions
Continued Therapy — Covered when ALL of the following are met for continued therapy.
Covered when ALL of the following are met for continued therapy:
Continuation requires prior plan approval or meeting initial criteria and evidence of ongoing ability to manage the device.
This policy sets the conditions under which disposable insulin infusion pumps (single‑use/patch devices) will be authorized. Coverage is conditional—the device is approved only when it is being used for an FDA‑approved indication and the member meets the plan’s specific clinical criteria for either initial therapy or continued therapy. Key thresholds include chart documentation within the past 180 days, ≥3 injections/day for Type 2 initial eligibility, and ≥4 blood glucose checks per day or use of a CGM.
Requests that do not include the required documentation or fail to meet the stated criteria will not be authorized. Specifically, authorization depends on chart notes within the last 180 days documenting the diabetes diagnosis and required insulin regimen/monitoring, and evidence that at least one of the listed clinical problems is present (eg, HbA1c >7%, recurrent hypoglycemia, large glucose variability, dawn phenomenon with fasting values frequently >200 mg/dL, or severe glycemic excursions). Absence of these items is a common trigger for denial.
Coding & Key Clinical Thresholds
| Omnipod 5 | example listed disposable infusion pump |
| Omnipod Dash | example listed disposable infusion pump |
| Omnipod Pods | example listed disposable infusion pump |
Provider Actions / Prior Authorization
Prior authorization required for disposable infusion pumps
Prior authorization is required for disposable infusion pumps (examples listed by the plan). Requests for devices such as Omnipod 5, Omnipod Dash, and Omnipod Pods must be submitted for prior authorization; approval requires meeting the plan's initial or continued therapy criteria.
- Examples listed: Omnipod 5, Omnipod Dash, Omnipod Pods
- Approval contingent on meeting initial or continued therapy criteria
No step therapy specified
The policy does not specify any step therapy requirements or a stepwise trial sequence for disposable infusion pumps.
Required documentation (chart notes within past 180 days)
Provide chart notes within the past 180 days documenting the diabetes diagnosis and current insulin regimen, plus evidence of blood glucose monitoring or CGM use and documentation supporting one of the specified clinical criteria.
- Chart notes within past 180 days documenting Type 1 diabetes OR Type 2 diabetes requiring insulin therapy
- For Type 2 initial requests: documentation that patient is on an insulin regimen of 3 or more injections per day
- Evidence that patient performs ≥4 blood glucose tests per day or is using a Continuous Glucose Monitor (CGM)
- Documentation supporting one qualifying clinical finding while on an optimized multiple daily injection regimen (HbA1c >7%; history of recurring hypoglycemia; wide glucose fluctuations; dawn phenomenon with fasting sugars frequently >200 mg/dL; or history of severe glycemic excursions)
Common triggers for denial
Requests may be denied if required chart documentation is missing or the patient does not meet the diabetes, regimen, monitoring, or clinical criteria specified by the plan.
- Chart notes do not document Type 1 diabetes or Type 2 diabetes requiring insulin therapy within the past 180 days
- For Type 2, patient is not on an insulin regimen of 3 or more injections per day
- No evidence of performing ≥4 blood glucose tests per day and no CGM use documented
- No documentation of one of the qualifying clinical problems (HbA1c >7%, recurring hypoglycemia, wide glucose fluctuations, dawn phenomenon with fasting >200 mg/dL, or severe glycemic excursions)
Background
Disposable insulin pumps (also called patch or single‑use infusion pumps) provide continuous subcutaneous insulin delivery for patients who require insulin therapy. The plan evaluates candidates who are insulin‑requiring, who perform frequent glucose monitoring or use CGM, and who continue to have clinically significant glycemic problems (for example, elevated HbA1c, recurrent hypoglycemia, wide glucose swings, or dawn phenomenon) despite optimized multiple daily injection regimens.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.